Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation
Open Access
- 31 December 2010
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 5 (12), 2039-2040
- https://doi.org/10.1097/jto.0b013e3181f43274
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialThe Lancet Oncology, 2009
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion GeneAnnals of Surgical Oncology, 2009
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinomaEuropean Respiratory Journal, 2008